CHICAGO—When a patient with rheumatic disease suffers recurrent infections, has a history of multiple autoimmune diseases or presents with atypical autoimmune syndromes, clinicians should consider the possibility of an immune deficiency, an expert said at the ACR State-of-the-Art Clinical Symposium in April.
W. Winn Chatham, MD, professor of medicine at the University of Alabama at Birmingham School of Medicine, said immune deficiency is frequently coupled with rheumatic disease. Patients with the most often seen form, common variable immune deficiency (CVID), have an autoimmune disorder 20–25% of the time, so clinicians must be aware of the signs and know how to manage it.
The atypical autoimmune syndromes often can’t be attributed to a specific rheumatologic diagnosis, he said. “Most notably, you see this a lot with patients who have seronegative RA,” Dr. Chatham said.
Immunodeficiency may develop in the setting of autoimmune disease because therapy (e.g., cyclophosphamide or azathioprine) induces neutropenia or lymphopenia. Patients can also have primary immunodeficiency, which can arise from autoimmunity that affects the numbers or functions of lymphoid and phagocytic cells, he said.
Dr. Chatham suggested using a rule of 500s to mitigate the risk of immune deficiencies associated with immunosuppressive treatment. A neutrophil count below 500/mm3, a T lymphocyte count below 500/mm3 or an IgG serum level below 500 mg/dL is reason to consider a patient at risk of immune deficiency from prescribed therapies, he said.
Physicians can manage severe neutropenia with levofloxacin, low T lymphocytes with trimethoprim-sulfamethaxazole or dapsone, and low IgG counts with IVIG.
A low serum IgG level is an often overlooked sign, he said. “This is one I see that even [clinicians] in our own group, as well as other people in practice using aggressive therapies, probably don’t monitor quite often enough,” he said. “It is also important to remember to check immunoglobulin levels any time you see a patient with new-onset autoimmune disease. It really should be part of the diagnostic evaluation, I think.”
To assess for primary immune deficiency, clinicians can measure IgG and IgG subclass levels, check to see if pneumococcal IgG responses are robust after pneumococcal vaccination or order flow cytometry studies to measure circulating B and T cell levels.
“If you get a hit on these with a noted abnormality and suspect a patient has an underlying immune deficiency, genetic testing is actually getting quite reasonable now, quite affordable,” he said. A primary immunodeficiency gene panel can be ordered for a couple of hundred dollars, he said.